lung-cancer

BRCA1/2 mutations in lung cancer predict worse survival overall but better response to immunotherapy

BRCA1 and BRCA2 are well-known cancer genes in breast and ovarian cancer, but their role in lung cancer is less understood. This study used single-cell sequencing and multi-omics data to characterize how BRCA1/2 mutations reshape the tumor microenvironment in lung adenocarcinoma (LUAD).

Dan Manning

Dan Manning

— 1 min read
Share
BRCA1/2 mutations in lung cancer predict worse survival overall but better response to immunotherapy

BRCA1/2 mutations in lung cancer predict worse survival overall but better response to immunotherapy

BRCA1 and BRCA2 are well-known cancer genes in breast and ovarian cancer, but their role in lung cancer is less understood. This study used single-cell sequencing and multi-omics data to characterize how BRCA1/2 mutations reshape the tumor microenvironment in lung adenocarcinoma (LUAD).

The findings revealed a dual nature: BRCA1/2 mutations were associated with higher genomic instability and poorer overall prognosis. However, the same mutations predicted better clinical outcomes when patients received immune checkpoint blockade (ICB) therapy. This is likely because the genomic instability creates more neoantigens — molecular flags that help the immune system recognize and attack cancer cells.

The study also characterized specific changes in T cell composition and function within BRCA-mutant tumors, providing a molecular map of how these mutations influence the immune landscape. This could help identify which lung cancer patients are most likely to benefit from immunotherapy.

Key Findings

  • BRCA1/2 mutations in lung adenocarcinoma are associated with increased genomic instability
  • BRCA-mutant LUAD patients had poorer prognosis overall but better outcomes with immune checkpoint blockade
  • Single-cell sequencing revealed distinct immune cell compositions in BRCA-mutant tumors
  • T cell functional alterations were characterized in the BRCA-mutant tumor microenvironment
  • BRCA1/2 mutation status may serve as a predictive biomarker for immunotherapy response in lung cancer

Implications

These results suggest BRCA1/2 mutation testing could be added to the toolkit for identifying lung cancer patients most likely to benefit from immunotherapy. Oncologists managing NSCLC patients with BRCA mutations should consider ICB as a treatment strategy, and this data supports expanding BRCA testing beyond breast/ovarian cancers.

Caveats

Preprint, not yet peer reviewed. Multi-omics analysis is complex and findings need independent validation in prospective cohorts. The sample size and patient population details are not clear from the abstract alone. Summary based on abstract only.

Source: bioRxiv — 2026-04-11

Read more